08/20/2024 | Press release | Distributed by Public on 08/20/2024 04:04
Item 8.01 |
Other Events. |
Warrant Call Option Exercise
On August 20, 2024, Vaccinex, Inc. (the "Company") announced that it was calling for cancellation the warrants to purchase shares of the Company's common stock that the Company had issued in transactions in October 2023, November 2023, February 2024, and March 2024, for $0.0001 per warrant share, pursuant to terms of the warrants permitting the Company to call the warrants for cancellation following the announcement of a statistically significant increase in FDG-PETsignal in patients in the Company's SIGNAL-ADtrial of pepinemab for the treatment of Alzheimer's disease. Following the call, warrant holders will have either 20 or 30 trading days to exercise their warrants, as provided in the applicable warrants. To the extent they are not timely exercised, the warrants will be automatically canceled. The Company intends to explore additional financing options in connection with the call of the warrants, which could include warrant inducement or exchange transactions. There is no guarantee that any of the warrants will be exercised following the call of the warrants, or that additional financing options in connection with the call of the warrants will be successful or at terms acceptable to the Company.